Axonics, Inc. (NASDAQ:AXNX – Get Rating) EVP John Woock sold 30,215 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $67.34, for a total value of $2,034,678.10. Following the completion of the transaction, the executive vice president now directly owns 45,976 shares in the company, valued at approximately $3,096,023.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Axonics Trading Down 0.3 %
NASDAQ:AXNX opened at $61.84 on Friday. Axonics, Inc. has a 12-month low of $38.41 and a 12-month high of $79.92. The stock has a 50-day moving average price of $63.46 and a 200 day moving average price of $67.10. The stock has a market capitalization of $3.06 billion, a P/E ratio of -37.48 and a beta of 0.43.
Axonics (NASDAQ:AXNX – Get Rating) last released its earnings results on Monday, October 31st. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13. Axonics had a negative return on equity of 15.63% and a negative net margin of 31.35%. The firm had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same quarter last year, the business posted ($0.38) earnings per share. The firm’s revenue was up 50.0% on a year-over-year basis. On average, research analysts predict that Axonics, Inc. will post -1.59 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Institutional Trading of Axonics
Several institutional investors have recently made changes to their positions in AXNX. JPMorgan Chase & Co. grew its holdings in Axonics by 6.3% during the 1st quarter. JPMorgan Chase & Co. now owns 98,932 shares of the company’s stock valued at $6,192,000 after buying an additional 5,867 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Axonics by 6.7% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 5,207 shares of the company’s stock valued at $326,000 after buying an additional 326 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Axonics by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 209,484 shares of the company’s stock valued at $13,114,000 after buying an additional 2,038 shares in the last quarter. US Bancorp DE grew its holdings in Axonics by 15.5% during the 1st quarter. US Bancorp DE now owns 2,508 shares of the company’s stock valued at $157,000 after buying an additional 337 shares in the last quarter. Finally, Group One Trading L.P. grew its holdings in Axonics by 1,159.5% during the 1st quarter. Group One Trading L.P. now owns 5,038 shares of the company’s stock valued at $315,000 after buying an additional 4,638 shares in the last quarter. Hedge funds and other institutional investors own 97.49% of the company’s stock.
Axonics Company Profile
Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.
- Get a free copy of the StockNews.com research report on Axonics (AXNX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.